Clinical observation of dapagliflozin in the treatment of heart failure combined with chronic kidney disease
- VernacularTitle:达格列净治疗心力衰竭合并慢性肾脏病的临床观察
- Author:
Zhiyun YANG
1
;
Yongjun ZHU
2
;
Feng CAI
3
;
Hongyan MA
4
;
Aiying TIAN
5
Author Information
1. School of Clinical Medicine，Shangqiu Medical College，Henan Shangqiu 476000，China
2. Dept. of Cardiology，Shangqiu First People’s Hospital/the First Affiliated Hospital of Shangqiu Medical College，Henan Shangqiu 476100，China
3. Dept. of Gastroenterology and Hepatobiliary Surgery，Shangqiu First People’s Hospital/the First Affiliated Hospital of Shangqiu Medical College，Henan Shangqiu 476100，China
4. Diagnostic Teaching and Research Office，Shangqiu Medical College，Henan Shangqiu 476000，China
5. Dept. of Gastroenterology，Shangqiu First People’s Hospital/the First Affiliated Hospital of Shangqiu Medical College，Henan Shangqiu 476100，China
- Publication Type:Journal Article
- Keywords:
dapagliflozin;
heart failure;
chronic kidney disease;
cardiac function;
renal function;
safety
- From:
China Pharmacy
2024;35(20):2512-2516
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To explore the effect and safety of dapagliflozin on cardiac function and renal function， blood glucose， and quality of life in patients with heart failure （HF） combined with chronic kidney disease （CKD）. METHODS A total of 156 patients with HF combined with CKD admitted to Shangqiu First People’s Hospital from January 1， 2021 to January 1， 2023 were included. According to the random number table， the patients were randomly divided into conventional treatment group （n＝80） and dapagliflozin group （n＝76）. Conventional treatment group was given conventional treatment； dapagliflozin group was additionally given Dapagliflozin tablets 10 mg orally， once a day， based on conventional treatment group. Both groups were treated for 6 months. Cardiac function [left ventricular ejection fraction （LVEF）， left ventricular end-systolic diameter （LVESD）， left ventricular end-diastolic diameter （LVEDD）， N-terminal pro-brain natriuretic peptide （NT-proBNP）]， renal function [blood creatinine， urea nitrogen， urinary albumin excretion rate （UAER）， glomerular filtration rate （GFR）， creatinine 806731979@qq.com clearance rate （CCR）]， glycosylated hemoglobin， and the quality of life were observed in 2 groups before and after treatment. The occurrence of ADR was recorded. RESULTS After treatment， LVESD， LVEDD， NT-proBNP， blood creatinine， urea nitrogen， UAER in 2 groups as well as the level of glycosylated hemoglobin in dapagliflozin group were significantly lower than before treatment； the dapagliflozin group was significantly lower than the conventional treatment group. LVEF， GFR， CCR and Kansas City Cardiomyopathy Questionnaire score were significantly higher than before treatment， and the dapagliflozin group was significantly higher than the conventional treatment group （P＜0.05）. There was no statistical significance in glycosylated hemoglobin of conventional treatment group before and after treatment （P＞ 0.05）. There was no statistically significant difference in the incidence of dizziness， rash， liver dysfunction， urinary system infection， new dialysis and hypotension between the two groups （P＞0.05）. CONCLUSIONS Dapagliflozin can improve the cardiac function and renal function of patients with HF complicated with CKD， improve patients’ quality of life and lower blood sugar levels without increasing the risk of adverse events.
